Please login to the form below

Not currently logged in
Email:
Password:

trial failures

This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the Atlantic, four years after a pair of trial failures left its future ... Dacomitinib missed its objectives in two phase III trials reported in

Latest news

  • Pharma sales help Bayer escape the worst from a bumpy 2017 Pharma sales help Bayer escape the worst from a bumpy 2017

    easy”. For its pharmaceuticals business the ‘downs’included several late-stage trial failures towards the end of the year. ... Among them were a 7, 000 patient study of Xarelto in secondary stroke, a combination trial of Eylea and a drug-device

  • Merck BACE inhibitor adds to litany of Alzheimer's trial failures Merck BACE inhibitor adds to litany of Alzheimer's trial failures

    Merck BACE inhibitor adds to litany of Alzheimer's trial failures. Interim data shows “ virtually no chance” of clinical success for verubecestat. ... The EPOCH trial enrolled patients with established mild-to-moderate Alzheimer symptoms and was due

  • Choose or lose Choose or lose

    In essence, it involves sifting through thousands of 'industry episodes' such as launches, trial results, acquisitions and failures. ... The latest trial results from Amgen point out how its model is trying to create clear space from statins.

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    Tau protein drug fails late-stage trial. Alzheimer’ s disease therapy only showed benefit in patients with no existing treatments. ... Much of the pharma industry's efforts in Alzheimer's have been directed at the amyloid plaques seen in the brains of

  • Double trial disappointment for Roche Double trial disappointment for Roche

    Roche's pipeline took a double hit today with disappointing trial results in both Alzheimer's disease and oncology. ... in the area considering multiple trial failures for investigational treatments in a later stage of the neurological condition.

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. “ ... Some companies already have their biobetter pipelines in clinical trial stage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics